Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Fisher Asset Management LLC

Fisher Asset Management LLC raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 16.5% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,890 shares of the biopharmaceutical company’s stock after purchasing an additional 833 shares during the period. Fisher Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $4,197,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of REGN. SVB Wealth LLC bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $707,000. Illumine Investment Management LLC acquired a new position in Regeneron Pharmaceuticals during the 4th quarter worth $2,130,000. Anchor Capital Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth $7,727,000. Generali Investments Towarzystwo Funduszy Inwestycyjnych increased its holdings in shares of Regeneron Pharmaceuticals by 27.7% during the fourth quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 1,401 shares of the biopharmaceutical company’s stock valued at $998,000 after purchasing an additional 304 shares during the period. Finally, Proficio Capital Partners LLC raised its stake in shares of Regeneron Pharmaceuticals by 92,865.3% during the fourth quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company’s stock valued at $156,284,000 after purchasing an additional 219,162 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on REGN shares. TD Cowen lowered their target price on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research note on Tuesday, February 4th. Bank of America reissued an “underperform” rating and set a $565.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Citigroup decreased their price target on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Bernstein Bank dropped their price objective on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Finally, Oppenheimer decreased their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Trading Down 1.4 %

Shares of NASDAQ REGN opened at $675.49 on Wednesday. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a one year low of $642.00 and a one year high of $1,211.20. The business has a 50-day moving average price of $697.13 and a two-hundred day moving average price of $859.13. The firm has a market capitalization of $73.85 billion, a PE ratio of 17.65, a PEG ratio of 2.34 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the company posted $11.86 earnings per share. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.52%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.